Immunitybio Share Price Today
(NASDAQ: IBRX)

Name: Immunitybio Share Price Today (NASDAQ: IBRX) - Immunitybio Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Immunitybio share price is $3.45 & ₹298.91 as on 1 Feb 2025, 2.30 'hrs' IST

$3.45

▲

-0.02

(-0.58%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Immunitybio share price in Dollar and Rupees. Guide to invest in Immunitybio stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Immunitybio, along with analyst recommendations, forecasts, and comprehensive financials.

Immunitybio share price movements

Today's Low: $3.37
Today's High: $3.65
$3.45
2.32%
Downside
Day's Volatility :7.63%
Upside
5.44%
52 Weeks Low: $2.28
52 Weeks High: $10.53
$3.45
33.91%
Downside
52 Weeks Volatility :78.35%
Upside
67.24%

Immunitybio (IBRX) Returns

Period	Immunitybio Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-33.65%	-0.6%	0.0%
6 Months	-21.59%	-2.8%	0.0%
1 Year	-16.67%	3.3%	0.0%
3 Years	-39.47%	11.6%	-13.7%

Immunitybio (IBRX) Key Statistics

in dollars & INR

Previous Close	$3.47
Open	$3.45
Today's High	$3.6484
Today's Low	$3.37
Market Capitalization	$2.5B
Today's Volume	$5.9M
52 Week High	$10.53
52 Week Low	$2.28
Revenue TTM	$7.3M
EBITDA	$-341.3M
Earnings Per Share (EPS)	$-0.9
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	0.0%

How to invest in Immunitybio Stock (IBRX) from India?

It is very easy for Indian residents to invest directly in Immunitybio from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Immunitybio stock in both Indian Rupees (INR) and US Dollars (USD). Search for Immunitybio or IBRX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Immunitybio or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Immunitybio shares which would translate to 0.251 fractional shares of Immunitybio as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Immunitybio, in just a few clicks!

Returns in Immunitybio (IBRX) for Indian investors in Rupees

The Immunitybio stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Immunitybio investment value today

Current value as on today

₹87,893

Returns

₹12,107

(-12.11%)

Returns from Immunitybio Stock

₹16,667 (-16.67%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Immunitybio (IBRX)

-35.36%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Investment in Immunitybio Shares from India has dropped by -35.36% over the past 30 days, indicating reduced transactional activity.

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Immunitybio Stock from India on INDmoney has increased by 1% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Immunitybio

Vanguard Group Inc
2.31%
BlackRock Inc
1.62%
State Street Corp
1.19%
Geode Capital Management, LLC
0.53%
Morgan Stanley - Brokerage Accounts
0.31%
Bank of America Corp
0.28%

Analyst Recommendation on Immunitybio

Buy

75%Buy

25%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Immunitybio(by analysts ranked 0 to 5 stars)

Based on 8 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Immunitybio Stock (IBRX)

What analysts predicted

Upside of 253.26%

Target:

$12.19

Current:

$3.45

Insights on Immunitybio Stock (Ticker Symbol: IBRX)

Price Movement
In the last 7 days, IBRX stock has moved up by 8.8%
Increasing Revenue
Revenue is up for the last 3 quarters, 40.0K → 6.10M (in $), with an average increase of 89.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -134.56M → -85.72M (in $), with an average increase of 57.0% per quarter
IBRX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 55.1% return, outperforming this stock by 60.6%
IBRX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 87.2% return, outperforming this stock by 130.5%
Price to Sales
ForIBRX every $1 of sales, investors are willing to pay $313.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.4 for every $1 of sales.

IBRX Immunitybio Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$47.0K	↑ 4.44%
Net Income	$-96.2M	↓ 0.2%
Net Profit Margin	-204.7K%	↑ 9537.16%

	FY19	Y/Y Change
Revenue	$2.2M	↑ 4585.11%
Net Income	$-160.2M	↑ 66.44%
Net Profit Margin	-7.3K%	↑ 197462.87%

	FY20	Y/Y Change
Revenue	$605.0K	↓ 72.52%
Net Income	$-224.2M	↑ 39.98%
Net Profit Margin	-37.1K%	↓ 29782.4%

	FY21	Y/Y Change
Revenue	$934.0K	↑ 54.38%
Net Income	$-349.8M	↑ 56.05%
Net Profit Margin	-37.5K%	↓ 401.26%

	FY22	Y/Y Change
Revenue	$240.0K	↓ 74.3%
Net Income	$-417.3M	↑ 19.29%
Net Profit Margin	-173.9K%	↓ 136426.37%

	FY23	Y/Y Change
Revenue	$622.0K	↑ 159.17%
Net Income	$-583.2M	↑ 39.75%
Net Profit Margin	-93.8K%	↑ 80121.92%

	Q2 FY23	Q/Q Change
Revenue	$41.0K	↓ 88.61%
Net Income	$-137.9M	↓ 8.79%
Net Profit Margin	-336.3K%	↓ 294300.8%

	Q3 FY23	Q/Q Change
Revenue	$82.0K	↑ 100.0%
Net Income	$-95.6M	↓ 30.68%
Net Profit Margin	-116.6K%	↑ 219726.83%

	Q4 FY23	Q/Q Change
Revenue	$139.0K	↑ 69.51%
Net Income	$-233.4M	↑ 144.18%
Net Profit Margin	-167.9K%	↓ 51344.5%

	Q1 FY24	Q/Q Change
Revenue	$40.0K	↓ 71.22%
Net Income	$-134.1M	↓ 42.54%
Net Profit Margin	-335.3K%	↓ 167364.59%

	Q2 FY24	Q/Q Change
Revenue	$1.0M	↑ 2517.5%
Net Income	$-134.6M	↑ 0.34%
Net Profit Margin	-12.9K%	↑ 322420.16%

	Q3 FY24	Q/Q Change
Revenue	$6.1M	↑ 483.19%
Net Income	$-85.7M	↓ 36.29%
Net Profit Margin	-1.4K%	↑ 11448.33%

	FY18	Y/Y Change
Profit	$47.0K	↑ 4.44%

	FY19	Y/Y Change
Profit	$-6.8M	↓ 14589.36%

	FY20	Y/Y Change
Profit	$-8.5M	↑ 25.43%

	FY21	Y/Y Change
Profit	$934.0K	↓ 110.93%

	FY22	Y/Y Change
Profit	$-24.0M	↓ 2664.45%

	FY23	Y/Y Change
Profit	$622.0K	↓ 102.6%

	Q2 FY23	Q/Q Change
Profit	$-6.3M	↑ 6.07%

	Q3 FY23	Q/Q Change
Profit	$-4.5M	↓ 28.26%

	Q4 FY23	Q/Q Change
Profit	$-4.4M	↓ 1.73%

	Q1 FY24	Q/Q Change
Profit	$-4.5M	↑ 2.03%

	Q2 FY24	Q/Q Change
Profit	$1.0M	↓ 123.19%

	Q3 FY24	Q/Q Change
Profit	$6.1M	↑ 483.19%

	FY18	Y/Y Change
Operating Cash Flow	$-63.4M	↑ 29.93%
Investing Cash Flow	$25.7M	↓ 74.2%
Financing Cash Flow	$-771.0K	↓ 97.8%

	FY19	Y/Y Change
Operating Cash Flow	$-152.1M	↑ 139.99%
Investing Cash Flow	$-6.3M	↓ 124.59%
Financing Cash Flow	$114.3M	↓ 14922.18%

	FY20	Y/Y Change
Operating Cash Flow	$-171.7M	↑ 12.9%
Investing Cash Flow	$-1.4M	↓ 78.29%
Financing Cash Flow	$150.7M	↑ 31.85%

	FY21	Y/Y Change
Operating Cash Flow	$-274.4M	↑ 59.8%
Investing Cash Flow	$-84.9M	↑ 6091.54%
Financing Cash Flow	$505.4M	↑ 235.45%

	FY22	Y/Y Change
Operating Cash Flow	$-337.5M	↑ 22.99%
Investing Cash Flow	$27.3M	↓ 132.16%
Financing Cash Flow	$233.6M	↓ 53.78%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-79.8M	↓ 5.38%
Investing Cash Flow	$-8.6M	↑ 1.41%
Financing Cash Flow	$43.4M	↓ 43.54%

Immunitybio Technicals Summary

Sell

Neutral

Buy

Immunitybio is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Immunitybio (IBRX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Immunitybio Inc.	34.24%	-21.59%	-16.67%	-39.47%	-89.38%
Biontech Se	7.35%	57.95%	33.59%	-31.3%	308.89%
Regeneron Pharmaceuticals, Inc.	-5.9%	-37.18%	-28.8%	8.05%	97.29%
Vertex Pharmaceuticals Incorporated	13.78%	-3.19%	8.71%	82.07%	100.29%
Alnylam Pharmaceuticals, Inc.	16.13%	2.38%	56.77%	86.78%	136.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Immunitybio Inc.	NA	NA	NA	-0.67	0.0	-0.56	NA	-1.07
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.89	16.89	1.06	44.96	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.15	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Immunitybio Inc.	Buy	$2.5B	-89.38%	NA	0.0%
Biontech Se	Buy	$29.0B	308.89%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.1B	97.29%	16.89	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$112.9B	100.29%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.7B	136.62%	NA	-15.86%

Immunitybio Dividend announcements

Immunitybio Earnings
Immunitybio’s price-to-earnings ratio stands at None
Read More

About Immunitybio

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Organization	Immunitybio
Employees	672
CEO	Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.
Industry	Healthcare

Management People of Immunitybio

Name	Title
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.	Executive Chairman of the Board and Global Chief Scientific & Medical Officer
Mr. Richard Gerald Adcock	President, CEO & Director
Mr. David C. Sachs	Chief Financial Officer
Dr. Barry J. Simon M.D.	Chief Corporate Affairs Officer & Director
Dr. Leonard S. Sender M.D.	Chief Operating Officer
Ms. Regan J. Lauer	Chief Accounting Officer
Dr. Enrique Diloné Ph.D., RAC	Chief Technology Officer
Mr. Jason R. Liljestrom J.D.	General Counsel & Corporate Secretary
Ms. Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy
Dr. Sandeep K. Reddy M.D.	Chief Medical Officer

Important FAQs about investing in IBRX Stock from India :

What is Immunitybio share price today?

Immunitybio share price today stands at $3.45, Open: $3.45 ; Previous Close: $3.47 ; High: $3.65 ; Low: $3.37 ; 52 Week High: $10.53 ; 52 Week Low: $2.28.

The stock opens at $3.45, after a previous close of $3.47. The stock reached a daily high of $3.65 and a low of $3.37, with a 52-week high of $10.53 and a 52-week low of $2.28.

Can Indians buy Immunitybio shares?

Yes, Indians can invest in the Immunitybio (IBRX) from India.

With INDmoney, you can buy Immunitybio at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Immunitybio at zero transaction cost.

How can I buy Immunitybio shares from India?

It is very easy to buy Immunitybio from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Immunitybio (IBRX) be purchased?

Yes, you can buy fractional shares of Immunitybio with INDmoney app.

What are the documents required to start investing in Immunitybio stocks?

To start investing in Immunitybio, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.